Ken Griffin Immuneering Corp Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Immuneering Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 1,882,136 shares of IMRX stock, worth $3.52 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,882,136
Previous 1,882,200
0.0%
Holding current value
$3.52 Million
Previous $5.44 Million
55.71%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding IMRX
# of Institutions
54Shares Held
9.63MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.07MShares$2 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny953KShares$1.78 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD859KShares$1.61 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY742KShares$1.39 Million0.0% of portfolio
-
Prosight Management, LP Dallas, TX550KShares$1.03 Million0.22% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $49.4M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...